The antitumor activity of roscovitine was tested in four cervical carcinoma cells: C33A, HCE‐
1, HeLa, and SiHa. The effects of roscovitine on ATP Lite assay, cell cycle, and apoptosis …

Apoptosis induction is a well-known strategy to mitigate the growth of cancerous cells. The
aim of this study is to determine the possibility of using roscovitine as a reference agent for …

Exposure of human HeLaS3 cervix carcinoma cells to high doses of conventional cytostatic
drugs, eg cisplatin (CP) strongly inhibits their proliferation. However, most cytostatic agents …

Purine analogue roscovitine, a cyclin-dependent kinase (CDK) inhibitor, has shown strong
anti-proliferative and pro-apoptotic effects in solid and hematologic cancers such as non …

Exposure of asynchronously growing human HeLa cervical carcinoma cells to roscovitine
(ROSC), a selective cyclin‐dependent kinases (CDKs) inhibitor, arrests their progression at …

We have previously shown (Mgbonyebi et al., Anticancer Res., 18: 751–756, 1998) that
roscovitine, an olomoucine-related purine analogue and a selective inhibitor of cyclin …

Roscovitine (2-(R)-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine, is a
potent and selective inhibitor of cyclin-dependent kinases (CDKs). It inhibits cdc2, cdk2 …

Raman micro-spectroscopic analysis of cultured HCT116 colon cancer cells in the presence
of roscovitine,[seliciclib, 2-(1-ethyl-2-hydroxy-ethylamino)-6-benzylamino-9-isopropylpurine] …

AIM: To examine the ability of cyclin-dependent kinase inhibitor (CDKI) roscovitine (Rosco)
to enhance the antitumor effects of conventional chemotherapeutic agents acting by different …

Roscovitine has been reported to have anti-tumor effects in some cancer cell lines. The
phosphatidylinositol-3-kinase (PI3K) signaling, which activates protein kinase B (PKB)/Akt, is …